Research ArticleClinical Studies
Association Between Immune-related Adverse Events and Clinical Outcome Following Nivolumab Treatment in Patients With Metastatic Renal Cell Carcinoma
KAZUO KOBAYASHI, YUSUKE IIKURA, MAKOTO HIRAIDE, TAKASHI YOKOKAWA, TAKESHI AOYAMA, SARI SHIKIBU, KOKI HASHIMOTO, KENICHI SUZUKI, HITOSHI SATO, ERIKA SUGIYAMA, MASATAKA TAJIMA and TOSHIHIRO HAMA
In Vivo September 2020, 34 (5) 2647-2652; DOI: https://doi.org/10.21873/invivo.12083
KAZUO KOBAYASHI
1Department of Pharmacy, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan
2Division of Pharmacokinetics and Pharmacodynamics, Department of Pharmacology, Toxicology and Therapeutics, School of Pharmacy, Showa University, Tokyo, Japan
YUSUKE IIKURA
1Department of Pharmacy, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan
MAKOTO HIRAIDE
3Division of Applied Pharmaceutical Education and Research Hoshi University, Tokyo, Japan
TAKASHI YOKOKAWA
1Department of Pharmacy, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan
TAKESHI AOYAMA
1Department of Pharmacy, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan
SARI SHIKIBU
1Department of Pharmacy, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan
KOKI HASHIMOTO
1Department of Pharmacy, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan
KENICHI SUZUKI
3Division of Applied Pharmaceutical Education and Research Hoshi University, Tokyo, Japan
HITOSHI SATO
2Division of Pharmacokinetics and Pharmacodynamics, Department of Pharmacology, Toxicology and Therapeutics, School of Pharmacy, Showa University, Tokyo, Japan
ERIKA SUGIYAMA
2Division of Pharmacokinetics and Pharmacodynamics, Department of Pharmacology, Toxicology and Therapeutics, School of Pharmacy, Showa University, Tokyo, Japan
MASATAKA TAJIMA
2Division of Pharmacokinetics and Pharmacodynamics, Department of Pharmacology, Toxicology and Therapeutics, School of Pharmacy, Showa University, Tokyo, Japan
TOSHIHIRO HAMA
1Department of Pharmacy, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan
In this issue
In Vivo
Vol. 34, Issue 5
September-October 2020
Association Between Immune-related Adverse Events and Clinical Outcome Following Nivolumab Treatment in Patients With Metastatic Renal Cell Carcinoma
KAZUO KOBAYASHI, YUSUKE IIKURA, MAKOTO HIRAIDE, TAKASHI YOKOKAWA, TAKESHI AOYAMA, SARI SHIKIBU, KOKI HASHIMOTO, KENICHI SUZUKI, HITOSHI SATO, ERIKA SUGIYAMA, MASATAKA TAJIMA, TOSHIHIRO HAMA
In Vivo Sep 2020, 34 (5) 2647-2652; DOI: 10.21873/invivo.12083
Association Between Immune-related Adverse Events and Clinical Outcome Following Nivolumab Treatment in Patients With Metastatic Renal Cell Carcinoma
KAZUO KOBAYASHI, YUSUKE IIKURA, MAKOTO HIRAIDE, TAKASHI YOKOKAWA, TAKESHI AOYAMA, SARI SHIKIBU, KOKI HASHIMOTO, KENICHI SUZUKI, HITOSHI SATO, ERIKA SUGIYAMA, MASATAKA TAJIMA, TOSHIHIRO HAMA
In Vivo Sep 2020, 34 (5) 2647-2652; DOI: 10.21873/invivo.12083
Jump to section
Related Articles
- No related articles found.